The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.
Issue link: https://lifescienceleadermag.epubxp.com/i/111709
Chiltern ��� Slough, UK www.chiltern.com ��� 44 1753 512 000 key locations: Asia Pacific, Eastern Europe, Latin America, North America, and Western Europe contact: Stuart McGuire ��� stuart.mcguire@chiltern.com Drug Life Cycle Stages: Research & Development ��� Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Clinical SERVICES & CAPABILITIES: Early phase, global clinical development, late phase, biometrics, medical & regulatory affairs, and resourcing solutions THERAPEUTIC AREAS: CNS, infectious diseases & vaccines, oncology, ophthalmology, pediatrics, and cardiorespiratory KEY INDUSTRY PARTNERS: endpoint, Medidata, Perceptive Informatics, Oracle, and Avoca Quality Consortium ���Chiltern is delighted to be recognized by members of the biopharmaceutical industry as a CRO leader in quality, reliability, productivity, innovation, and regulatory. Chiltern has been serving clients for more than 30 years and has established a track record around the world as an innovative, efficient, and flexible full service CRO. It is a great pleasure to accept this award on behalf of all Chiltern colleagues.��� ��� Jim Esinhart, CEO Comprehensive Clinical Development ��� Miramar, FL www.comprehensivecd.com ��� (954) 266-2620 key locations: California, Florida, Georgia, New York, Washington, and Washington, D.C. contact: Elizabeth Harley ��� eharley@comprehensivecd.com Drug Life Cycle Stages: Research & Development ��� Clinical (Phase 1, Phase 2, and Phase 3) Main Service Areas: Clinical SERVICES & CAPABILITIES: Clinical pharmacology units with full-service support for early phase studies, clinical research centers with highly-recognized CNS investigators, and a network of leading oncology, neurology and geriatric centers THERAPEUTIC AREAS: Addiction, cardiology, dermatology, endocrinology, immunology, infectious disease, metabolic disorders, neurology, oncology, psychiatry, and women���s health KEY INDUSTRY PARTNERS: Quintiles ���Comprehensive has grown from a tactical service provider to an integrated development partner, offering a portfolio of services and differentiated capabilities. We are proud of this achievement and our ability to accelerate the research process for our clients. Receiving this honor in the productivity category is a tribute to our employees who deliver professional study conduct services, meeting stringent timelines with the utmost quality.��� ��� Jack McGovern, CEO, comprehensive clinical development Covance Inc. ��� Princeton, NJ www.covance.com ��� (609) 452-4440 key locations: Brazil, China, Germany, Russia, Singapore, Switzerland, United Kingdom, & U.S. contact: Nigel Brown ��� nigel.brown@covance.com Drug Life Cycle Stages: Research & Development ��� Discovery, Preclinical, Clinical (Phase 1, Phase 2, and Phase 3) Drug Substance Production: Primary Process Development, Drug Substance Production Main Service Areas: Bioanalytical, Clinical, Preclinical SERVICES & CAPABILITIES: Pharmacology, bioanalysis and biopharmaceutical CMC (small and large molecule), ADME, non-clinical safety assessment, program management, clinical pharmacology and phase I/IIa trials, early clinical studies, proof-of-concept studies, phase IIb/III studies, and post-registration and phase IV studies THERAPEUTIC AREAS: Inflammation, dermatology, Oncology, GI, cardiovascular/metabolic, hematology, neuroscience, hormonal therapy, infectious disease, immunology, analgesic, ocular, antiinfectives, renal disease, CNS, and respiratory disease KEY INDUSTRY PARTNERS: Covance works with all of the top pharmaceutical companies, as well as scores of small and emerging biopharmaceutical companies. We also have publicly announced strategic alliances or collaborations with Eli Lilly and Company, Sanofi, Merck, Takeda, and Bayer. ���In an environment where every day and every data point counts, it���s our relentless commitment to operational and service excellence that earns client trust and confidence. Our talented teams of professionals, with deep drug development expertise, create innovative processes and proprietary analytic tools to deliver what our clients need: high-quality data, consistent project performance, and accelerated timelines.��� ��� Joe Herring, chairman and chief executive officer 24 The CRO Leadership Awards 2013